medigraphic.com
Academia Mexicana de Neurología, A.C.

2010, Number 1

<< Back Next >>

Rev Mex Neuroci 2010; 11 (1)

Neuroscience and current treatment of addictions

Souza MM, Cruz ML

Language: Spanish
References: 76
Page: 33-38
PDF size: 59.39 Kb.


ABSTRACT

International data found that the severity of the problem epidemiological, clinical comprehensive assessments recommend to patients abusers/addicts and use of psychotropic diagnostic tools, whose efficiency makes them useful elements in certain brain pathologies. We describe the neuroanatomy-physiology of the areas involved in the production of addictive disease as a centre of management and long-term rehabilitation. It indicates the role of frontal cortical structures in human behaviour which disables alteration to the individual to assess the potential reward associated with self-medication. Emphasis is placed in the imagenological participation in the diagnosis and management of these disorders, techniques that make it over him without invading and where the identification of underlying neuro-biochemical mechanisms is crucial. It highlights the resources for better long term psychotherapeutic rehabilitation that joins the utility-educational information to patients and their families. Synergy pharmacological, psychological counseling and vocational favors the highest rate of abstinence and relapse prevention in disorders such as addiction to nicotine, which along with psychosocial support reach the goal of early referral of consumption and maintenance of sustained abstinence. The involvement of health personnel in educating patients and families gives the professional work force and contributes to the dissemination of health recommendations made to that effect, as strengthening management of individual cases, whose quality and warmth contributes to the decline in social stigma due to ignorance and misunderstanding of these disorders.


REFERENCES

  1. Souza y Machorro M. Adicciones; clínica y terapéutica. México: Editorial Alfil; 2007.

  2. Kandel DB, Johnson JG, Bird HR. Psychiatric comorbidity among adolescents with substance use disorders: findings from the MECA study. J Am Acad Child Adolesc Psychiatry 1999; 38: 693-6.

  3. Souza y Machorro M, Quijano BEM, Díaz Barriga S, Guisa CVM Lorenzo AS, Gaucin RR. Historia clínica psiquiátrica codificada para adicciones. HCPCA. Psiquiatría 1998; 14(1): 9-25.

  4. DiClemente RJ, Wingwood GM, Crosby R. Parental monitoring: association with adolescents’ risk behaviors. Pediatrics 2001; 107: 1363-8.

  5. Souza y Machorro M. Enseñanza e investigación sobre adicciones en la Ciudad de México. Psiquiatría 1998; 14(3): 100-6.

  6. Dias P. Adolescent substance abuse: assessment in the office. Pediatric Clinics North Am 2002; 49(2): 1-23.

  7. Crowley TJ, MacDonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 1998; 50: 27-37.

  8. Farrar HC, Kearns GL. Cocaine: clinical pharmacology and toxicology. J Pediatr 1989; 115: 665-75.

  9. Resnick MD, Bearman PS, Blum RW. Protecting adolescents from harm: findings from the national longitudinal study on adolescent health. JAMA 1997; 278: 823-32.

  10. Shippenberg TS, Elmer GI. The neurobiology of opiate reinforcement. Crit Rev Neurobiol 1998; 12: 267-303.

  11. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280: 1936-43.

  12. Harrison PA, Fulkerson JA, Beebe TJ. Multiple substance use among adolescent physical and sexual abuse victims. Child Abuse Neglect 1997; 21: 529-53.

  13. Warner EA, Kosten TR, O’Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am 1997; 81: 909-25.

  14. Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: II. Sequences of progression. Am J Public Health 1984; 74: 668-72.

  15. Kaul P, Coupey SM. Clinical Evaluation of Substance Abuse. Pediatrics in Review 2003; 23(3): 80-96.

  16. American Academy of Pediatrics. Center for Advanced Studies: risk factors and their implications for prevention interventions for the physician. In: Schonberg SK (eds.). Substance abuse: a guide for health professionals Elk Grove Village, IL: AAP; 1988, p. 1-10.

  17. Tagle OI, Mercado CG, Martínez AJ, Martínez MJ, Souza y Machorro M. Por qué profesionalizar la terapéutica de las adicciones. Psiquiatría 2000; 16(3): 110-16.

  18. Richardson JL, Dwyer K, McGuigan K, et al. Substance use among eighth-grade students who take care of themselves after school. Pediatrics 1989; 84: 556-66.

  19. Fishman M, Bruner A, Adger H. Substance abuse among children and adolescents. Pediatr Rev 1997; 18: 394-403.

  20. Johnson T, Hart H. Missed opportunity: the CASA National Survey of Primary Care Physicians and Patients Chicago, IL: Survey Research Laboratory; 2000, p. 1-113.

  21. Bernardt MW, Mumford J, Taylor C, et al. Comparison of questionnaire and laboratory tests in the detection of excessive drinking and alcoholism. Lancet 1982; 1: 325-8.

  22. Schwartz R. Testing for drugs of abuse: controversies and techniques. Adolesc Med 1993; 4: 353-70.

  23. Kann L, Kinchen SA, Williams BI, et al. Youth risk behavior surveillance. U.S.: 1999. MMWR: CDC Surveillance Summaries. Atlanta, Ga: United States Department of Health and Human Services, Centers for Disease Control and Prevention; 2000.

  24. Schwartz B, Alderman EM. Substances of abuse. Pediatr Rev 1997; 13: 204-15.

  25. Pouwels PJ, Brockmann K, Kruse B. Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS. Pediatr Res 1999; 46: 474-85.

  26. Ernst T, Chang L, Leonido-Yee M, Speck O. Evidence for long-term neurotoxicity associated with methamphetamine Abuse. A 1 H MRS Study. Neurology 2000; 54: 1344-9.

  27. Itti L, Chang L, Mangin JF, Darcourt J, Ernst T. Robust multimodality registration for brain mapping. Hum Brain Mapping 1997; 5: 3-17.

  28. Chang L, Grob CS, Ernst T. Effect of ecstasy [3,4- methylenedioxymethamphetamine (MDMA) on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res Neuroimaging 2000; 98: 15-28.

  29. Chang L, Mehringer CM, Ernst T. Neurochemical alterations in asymptomatic abstinent cocaine users: a proton magnetic resonance spectroscopy study. Biol Psychiatry 1997; 42: 1105-14.

  30. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993; 15: 289-98.

  31. Christensen JD, Kaufman MJ, Levin JM. Abnormal cerebral metabolism in polydrug abusers during early withdrawal: a 31P MR spectroscopy study. Magn Reson Med 1996; 35: 658-63.

  32. Holman LJ, Carvalho PA, Mendelson J. Brain perfusion is abnormal in cocaine-dependent polydrug users: a study using technetium-99 m-HMPAO and SPECT. J Nucl Med 1991; 32: 1206-10.

  33. Smith LM, Chang L, Yonekura ML, Gilbride K, Kuo J, Poland RE, Walot I, Ernst I. Brain Proton Magnetic Resonance Spectroscopy and Imaging in Children Exposed to Cocaine in Utero. Pediatrics 2001; 107(2): 108-20.

  34. Breiter HC, Rosen BR. Functional magnetic resonance imaging of brain reward circuitry in the human. Ann N Y Acad Sci 1999; 877: 523-47.

  35. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 1999; 13: 337-45.

  36. Behnke M, Davis Eyler F, Conlon M, Wobie K, Stewart Woods N, Cumming W. Incidence and description of structural brain abnormalities in newborns exposed to cocaine. J Pediatr 1998; 132: 291-4.

  37. Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamine use: incidence and clinical correlates. J Pediatr 1989; 115: 770-8.

  38. Fowler JS, Volkow ND. PET imaging studies in drug abuse. J Toxicol Clin Toxicol 1998; 36(3): 163-74.

  39. Vocci FJ, London ED. Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging. Ann N Y Acad Sci 1997; 820: 29-39.

  40. London ED, Grant SJ, Morgan MJ, Zukin SR. Neurobiology of drug abuse. In: Foguel BS, Schiffer RB, Rao SM (eds.). Neuropsychiatry: a comprehensive textbook, pp. 635-678. Baltimore, MD.: William and Wilkns; 1996.

  41. Sell LA, Morris J, Bearn J, Frackowiak RS, Friston KJ, Dolan RJ. Activation of reward circuitry in human opiate addicts. Eur J Neurosci 1999; 11: 1042-8.

  42. Souza y Machorro M. Craving, adicción etílica y terapéutica. Archivos de Neurociencias México 2000; 5(4): 201-4.

  43. Hof PR, Mofson EJ, Morrison JH. Human orbitofrontal cortex: cytoarchitecture and quantitative inmunohistochemical parcellation. J Comp Neurol 1995; 359: 48-64.

  44. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O’Brien CP. Limbic activation during cue-induced cocaine craving. Am J Psychiatry 1999; 156: 11-8.

  45. Breiter HC, Rauch SL. Functional MRI and the stuudy of OCD; from symptom provocation to cognitive-behabioral probes of cortico-striatal systems and the amygdala. Neuroimagine 1996; 3: S127-S138.

  46. Zald DH, Kim SW. Anatomy and function of the orbital frontal cortex. I Anatomy, neurochemistry; and obssesive-compulsive disorder. J Neuropsychiat Clin Neurosci 1996; 8: 125-38.

  47. Semple WE, Goyer P, Mc Cormick R, Morris E, Comptom B, Muswick G, et al. Preliminary report: Brain blood flow using PET in patients with posttraumatic stress disorder and substance abuse histories. Biol Psychiat 1993; 34: 115-18.

  48. Pardo JV, Pardo PJ, Rechle ME. Neural correlates of cell induced disforia. Am J Psychiat 1993; 150: 713-19.

  49. Baker SC, Frith CD, Dolan RJ. The interaction between mood and cognitive function studied with PET. Psychol Med 1997; 27: 565-78.

  50. Meyers CA, Berman Sa, Scheibel RS, Hayman A. Case report: acquiered antisocial personality disorder associatted with unilateral left orbital frontal lobe damage. J Psychiat Neurosci 1992; 17: 121-5.

  51. Fornazzari L, Farcnick K, Smith I, Heasman GA, Ichise M. Violent visual allucinations and agresion in frontal lobe disfunction. Clinical manifestations of deep orbitofrontal foci. J. Neuropsychiat Clin Neurosci 1992; 4: 42-4.

  52. Siever LJ, Buchsbaum MS, New AS, Speigel-Cohen J, Wei T, Hazlett EA, Sevin E, Nunn M, Mitropulou M. d-I-fenfluramine responde in impulsive personality disorder assessed with 18 F- fluorodeoxy-glucose positron emission tomography. Neuropsychopharmacology 1999; 20: 413-23.

  53. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to humane prefrontal cortex. Cognition 1994; 50: 7-15.

  54. Kilts CD. Imaging the roles of the amygdala in drug addiction. Psychopharmacol Bull 2001; 35(1): 84-94.

  55. London ED, Ernst M, Grannt S, Bonson K, Weinstein A. Orbitofrontal cortex and human drug abuse: Functional Imaging. Cerebral Cortex 2000; 10: 334-42.

  56. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159(10): 1642-52.

  57. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and Addiction in humans: results from imaging studies. Behav Pharmacol 2002; 13(5-6): 355-66.

  58. Tomkins DM, Sellers EM. Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence. Canadian Medical Association Journal 2001; 164(6): 20-38.

  59. Volkow ND, Wang GS, Fowler JS, Logan J, Gatley SJ, Wong C. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291: 409-15.

  60. Li TK. Pharmacogenetics of responses to alcohol and genes that influence alcohol drinking. J Stud Alcohol 2000; 61: 5-12.

  61. Guardia J, Catafau AM, Battle F, Martin JC, Segura L, Gonzalvo B, et al. Striatal dopaminergic D(2) receptor density measured by [(123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcohol-dependent patients. Am J Psychiatry 2000; 157: 127-9.

  62. Souza y Machorro M. Imagenología, neurociencia y adicciones. Rev Mex Neuroci 2006; 7(4); 278-81.

  63. Johnson BA, Ait-Daoud N. Neuropharmalogical treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 2000; 149: 327-44.

  64. Volpicelli JR, Alterman AI, Hayasgida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-80.

  65. Poldrugo F. Acamprosate treatment in a long term community-based alcohol rehabilitation program. Addiction 1997; 92: 1537-46.

  66. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997; 3: 129-37.

  67. Klein M. Research issues related to development of medications for treatment of cocaine addiction. Ann N Y Acad Sci 1998; 844: 75-91.

  68. Prado GA, Martínez AJ, M Martínez MJ, Mercado CG, Tagle OI, Souza y Machorro M. Adicciones y farmacoterapia: uso de bupropión en la dependencia a cocaína. Psiquiatría 2001; 17(2): 58-64.

  69. Souza y Machorro M. Por una psiquiatría de las adicciones. Rev Mex Neuroci 2003; 4(4): 206-8.

  70. Picciotto MR. Common aspects of the action of nicotine and other drugs of abuse. Drug Alcohol Depend 1998; 51: 165-72.

  71. Perkins KA, Sanders M, Fonte C, Wilson AS, White W, Stiller R. Effects of central and peripheral nicotinic blockade on human nicotine discrimination. Psychopharmacology 1999; 142: 158-64.

  72. Jorenby DE. New developments in approaches to smoking cessation. Curr Opin Pulm Med 1998; 4: 103-6.

  73. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999; 281: 72-6.

  74. Siegel S, Ramos BM. Applying laboratory research: drug anticipation and the treatment of drug addiction. Exp Clin Psychopharmacol 2002; 10(3): 162-83.

  75. Carroll KM, Schottenfeld R. Nonpharmacologic approaches to substance abuse treatment. Medical Clinics of North America 1997; 81(4): 927-44.

  76. Souza y Machorro M. Adicciones, psicopatología y psicoterapia. Rev Mex Neuroci 2004 5(1): 57-69.




2020     |     www.medigraphic.com